Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report
Published inChest, vol. 160, no. 6, p. 2247-2259
Publication date2021-12
First online date2021-08-02
Abstract
Keywords
- DVT
- Antithrombotic therapy
- Guidelines
- Pulmonary embolism
- Thrombosis
- Drug Therapy, Combination
- Evidence-Based Medicine
- Fibrinolytic Agents / therapeutic use
- Fondaparinux / therapeutic use
- Heparin, Low-Molecular-Weight / therapeutic use
- Humans
- Injections, Intravenous
- Injections, Subcutaneous
- International Normalized Ratio
- Pulmonary Embolism / drug therapy
- Risk Assessment
- Thrombolytic Therapy / methods
- Venous Thrombosis / drug therapy
- Vitamin K / antagonists & inhibitors
Affiliation entities
Research groups
Citation (ISO format)
STEVENS, Scott M et al. Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. In: Chest, 2021, vol. 160, n° 6, p. 2247–2259. doi: 10.1016/j.chest.2021.07.056
Main files (1)
Article (Published version)
Identifiers
- PID : unige:161702
- DOI : 10.1016/j.chest.2021.07.056
- PMID : 34352279
Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S0012369221015075
Journal ISSN0012-3692
